ADMA Biologics (NASDAQ:ADMA) Trading Up 7.6% – What’s Next?

Shares of ADMA Biologics Inc (NASDAQ:ADMA) traded up 7.6% on Wednesday . The company traded as high as $8.77 and last traded at $8.7350. 314,986 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 5,151,083 shares. The stock had previously closed at $8.12.

Analysts Set New Price Targets

Several brokerages have weighed in on ADMA. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Mizuho reduced their price target on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Raymond James Financial initiated coverage on shares of ADMA Biologics in a report on Wednesday. They issued an “outperform” rating and a $21.00 price target for the company. Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Finally, Canaccord Genuity Group cut their target price on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, ADMA Biologics currently has an average rating of “Hold” and an average target price of $19.67.

ADMA Biologics Price Performance

The firm has a market cap of $1.99 billion, a PE ratio of 12.64 and a beta of 0.72. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. The stock has a 50 day moving average price of $9.22 and a two-hundred day moving average price of $14.31.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, hitting analysts’ consensus estimates of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The firm had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. During the same quarter in the previous year, the company posted $0.11 earnings per share. The company’s revenue was down .3% compared to the same quarter last year. As a group, equities analysts expect that ADMA Biologics Inc will post 0.84 earnings per share for the current year.

Insider Activity at ADMA Biologics

In related news, Director Jerrold B. Grossman purchased 12,500 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $8.01 per share, with a total value of $100,125.00. Following the completion of the acquisition, the director owned 513,884 shares of the company’s stock, valued at $4,116,210.84. The trade was a 2.49% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.90% of the stock is owned by company insiders.

Institutional Trading of ADMA Biologics

Several large investors have recently added to or reduced their stakes in the stock. Lido Advisors LLC grew its holdings in ADMA Biologics by 3.8% in the 4th quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company’s stock valued at $312,000 after buying an additional 629 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in ADMA Biologics by 11.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 634 shares in the last quarter. Cim LLC grew its holdings in ADMA Biologics by 0.7% in the 3rd quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock valued at $1,341,000 after buying an additional 665 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in ADMA Biologics by 28.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 700 shares in the last quarter. Finally, Clearstead Advisors LLC lifted its stake in ADMA Biologics by 55.7% during the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 795 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.